BETA
Clinical-stage developer of Chondrograft, a synthetic 3D-printed implant and instrumentation system for investigational repair of focal knee cartilage defects.
Nanochon, Inc. is a medical-device developer founded in 2016. Its company LinkedIn profile lists Washington, District of Columbia as headquarters; company announcements also describe operations in Baltimore, Maryland. The company develops its own Chondrograft implant and related instrumentation.
Chondrograft is a porous, fully synthetic polymer scaffold intended to provide mechanical support and support tissue repair at damaged articular surfaces of the knee. Manufacturer documentation describes a Nylon 12 and polyvinyl alcohol composite. Regenerative language refers to the intended response to an implanted device; this is not a supplied cell therapy or tissue graft.
Chondrograft remains investigational and is not approved for marketing. Nanochon reports first-in-human implantation in Panama on August 29, 2026, announced September 2. Its proposed pivotal study, FDA submission and U.S. market entry remain future plans; clinical benefit and commercial authorization should not be inferred from early study activity.
Chondrograft is an investigational synthetic implant and instrumentation system. Published named searches did not identify a matching FDA 510(k) clearance, De Novo grant or PMA approval. The manufacturer explicitly states that the device is not approved for marketing; this review does not establish the status of confidential or pending applications. [1][11]
Nanochon reports an FDA Breakthrough Device designation. That statement is retained as manufacturer-reported because an independent designation document was not established in this review. Designation does not itself authorize commercial marketing or demonstrate clinical effectiveness. [5]
The company reports its first human procedure in Panama on August 29, 2026, announced September 2. This is early clinical investigation, not U.S. marketing authorization. Proposed pivotal-study and PMA plans are forward-looking; the reviewed sources do not establish a completed FDA submission or approval. [5][3]
Published FDA searches under the company and selected product names found no relevant original PMA approvals, De Novo grants or recall events. Unrelated name matches are excluded. [14][12][13][15]
Latest recorded source review: 2026-10-27.
No commercially marketed product portfolio has been established in the reviewed material.
Its 2026 third-quarter update describes ongoing clinical study, development of arthroscopic delivery and surgical-planning software, and a proposed $30 million Series A in Q1 2027. These are company-reported development and financing plans, not launched product lines, completed financing or annual revenue. No current individual vacancies were verified. [3]
Porous, 3D-printed Nylon 12 / polyvinyl alcohol implant with a dedicated instrumentation set. Intended to provide mechanical support and a scaffold for tissue repair; clinical benefit remains under investigation. [1][8][11][5]
Investigational; not approved for marketingAvailable for investigational clinical use at authorized study sites; not approved for marketing.
Accessed 10/29/2026
Last substantive review: 10/27/2026